Fisher Funds Management LTD Has $6.09 Million Stock Position in Abbott Laboratories $ABT

Fisher Funds Management LTD cut its holdings in Abbott Laboratories (NYSE:ABT) by 15.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 59,326 shares of the healthcare product maker’s stock after selling 10,709 shares during the quarter. Fisher Funds Management LTD’s holdings in Abbott Laboratories were worth $6,091,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. American National Bank of Texas increased its stake in shares of Abbott Laboratories by 2.4% in the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after acquiring an additional 79 shares in the last quarter. Nia Impact Advisors LLC boosted its stake in Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after acquiring an additional 79 shares in the last quarter. Park Place Capital Corp boosted its stake in Abbott Laboratories by 11.0% during the fourth quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock worth $102,000 after acquiring an additional 81 shares in the last quarter. Lantern Wealth Advisors LLC grew its holdings in Abbott Laboratories by 1.7% in the third quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock worth $674,000 after purchasing an additional 84 shares during the period. Finally, Clayton Financial Group LLC increased its stake in Abbott Laboratories by 1.4% in the fourth quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock valued at $779,000 after purchasing an additional 84 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Up 0.1%

Shares of NYSE ABT opened at $88.48 on Monday. The stock has a market capitalization of $154.12 billion, a P/E ratio of 24.78, a P/E/G ratio of 1.52 and a beta of 0.63. The company has a 50-day moving average price of $90.08 and a 200-day moving average price of $106.45. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same quarter in the prior year, the business posted $1.09 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. Abbott Laboratories’s dividend payout ratio is 70.59%.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction that occurred on Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

ABT has been the topic of a number of research analyst reports. JPMorgan Chase & Co. cut their price objective on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a research report on Wednesday, April 22nd. Bank of America dropped their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Leerink Partners cut their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a report on Tuesday, April 21st. Finally, Jefferies Financial Group reduced their price objective on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average target price of $118.30.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.